Peptron, Inc. (KOSDAQ:087010)

South Korea flag South Korea · Delayed Price · Currency is KRW
285,000
-1,500 (-0.52%)
At close: Feb 27, 2026
208.78%
Market Cap 6.65T
Revenue (ttm) 6.19B
Net Income (ttm) -14.19B
Shares Out 23.32M
EPS (ttm) -623.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,852
Average Volume 238,369
Open 279,500
Previous Close 286,500
Day's Range 279,000 - 289,500
52-Week Range 85,600 - 392,500
Beta 0.85
RSI 55.36
Earnings Date n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 087010
Full Company Profile

Financial Performance

In 2024, Peptron's revenue was 3.15 billion, a decrease of -5.68% compared to the previous year's 3.34 billion. Losses were -22.03 billion, 38.4% more than in 2023.

Financial Statements

News

There is no news available yet.